polvitolimod   Click here for help

GtoPdb Ligand ID: 11872

Synonyms: compound 32 [WO2019226977A1] [1]
Compound class: Synthetic organic
Comment: Polvitolimod is classified as a toll-like receptor agonist in WHO proposed INN list 126 (January 2022). It was included in the 'COVID' section of that list. Patent mining suggests that polvitolimod is a TLR7 agonist prodrug, that was developed by Primmune Therapeutics as a potential treatment of cancer and infectious disease. In patent WO2019226977 polvitolimod's chemical structure matches that of Compound 32 [1]. Assessment of Primmune Therapeutics' pipeline indicates that polvitolimod is likely to be their clinical candidate PRTX007. If this is the correct name-to-structure association the active drug (PRX034) is likely to be compound 27 as claimed in the patent.
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 6
Hydrogen bond donors 3
Rotatable bonds 3
Topological polar surface area 128.42
Molecular weight 323.1
XLogP -1.71
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES C#CCn1c(=O)n(c2c1cnc(n2)N)[C@@H]1O[C@@H]([C@H]([C@H]1O)F)CO
Isomeric SMILES Nc1ncc2n(c(=O)n(c2n1)[C@H]1[C@H](O)[C@@H]([C@H](O1)CO)F)CC#C
InChI InChI=1S/C13H14FN5O4/c1-2-3-18-6-4-16-12(15)17-10(6)19(13(18)22)11-9(21)8(14)7(5-20)23-11/h1,4,7-9,11,20-21H,3,5H2,(H2,15,16,17)/t7-,8-,9-,11-/m1/s1
InChI Key NPRYCHLHHVWLQZ-TURQNECASA-N